BioXcel Therapeutics (BTAI) Misses Q3 EPS by 17c

BioXcel Therapeutics (NASDAQ: BTAI) reported Q3 EPS of ($1.49), $0.17 worse than the analyst estimate of ($1.32). Revenue for the quarter came in at $140 thousand versus the consensus estimate of $1.12 million.

For earnings history and earnings-related data on BioXcel Therapeutics (BTAI) click here.

You May Also Be Interested In

• Meta capex to surge in 2027, neocloud fears ’erroneous’ - SemiAnalysis
• Morgan Stanley Resumes Kohl's (KSS) at Underweight
• Morgan Stanley Resumes Gap, Inc. (GAP) at Equalweight